投稿问答最小化  关闭

认证信息

广告

您的位置:万维书刊网 >> 期刊动态

《药学学报(英文版)》2017年作者指南(2017年05期)

2017/10/18 10:20:07  阅读:2062 发布者:
编者按:以下信息,由万维书刊网根据期刊2017年05期信息整理发布!

药学学报(英文版)》作者指南

Information for Authors

Acta Pharmaceutica Sinica B is an English language bimonthly peer-reviewed journal published online in ScienceDirect which invites research articles, reviews and communications in all areas of the pharmaceutical sciences. It is one of a series of Acta Pharmaceutica Sinica journals founded in 1953 and sponsored by the Institute of Materia Medica, Chinese Academy of Medical Sciences and the Chinese Pharmaceutical Association. It is produced and hosted by Elsevier B. V.

1. Scope of submitted manuscripts

The journal invites original articles and review papers dealing with all aspects of the pharmaceutical sciences including pharmacology, pharmaceutics, medicinal chemistry, natural products, pharmacognosy, pharmaceutical analysis and pharmacokinetics.

Review articles: These should encompass new and important aspects of study and should describe research results and provide a critical analysis of the issue.

Original articles: These should deal with new, significant and innovative findings based on recent research.

Communications: Articles should contain new and important information that is likely to be of interest to readers and makes urgent publication desirable.

2. Submissions of manuscripts

Manuscripts should be submitted online via EVISE® at http://www.evise.com/evise/faces/pages/navigation/NavController.jspx?JRNL_ACR=APSB by registering and logging into this website. The system is easy to use and allows authors to submit papers online and track their progress through the editorial process.

Prior or duplicate publications are not accepted. All manuscripts, especially data, must not have been published or submitted for publication elsewhere. The authors should make a full disclosure of any past submissions.

Submitted manuscripts should be accompanied by a covering letter giving: (1) the title of the manuscript; (2) a statement that the manuscript has not been published in part or whole (except in the form of abstract) nor is under consideration for publication elsewhere in any language.

The source of financial assistance and other support must be acknowledged. The contribution of colleagues or institutions should also be acknowledged.

3. Peer-review

3.1 Manuscript receipt

Upon receipt of a manuscript, the Editorial Office will immediately assign a code number which should be used in all subsequent correspondence. An acknowledgement of receipt letter will be sent to the corresponding author. After pre-review by the editors, most submitted manuscripts will be sent to expert reviewers for peer-review. All manuscripts are subject to editorial modification.

3.2 Revision

On receipt of comments from the Editorial Office, the authors should revise their manuscript, answer the comments one by one and indicate the page and line of each correction to the manuscript. A revised manuscript will be considered a new submission if not returned to the Editorial Office within 1 month. Revised versions labeled with the manuscript code number should be sent electronically or by e-mail.

3.3 Rejected manuscripts

If a manuscript is not accepted for publication, the authors will receive a decision letter along with the reviewers’ comments.

3.4 Proof reading

Checking the proofs is solely the authors’ responsibility. Answer any queries on the proof itself. Corrections are restricted to printer’s errors and should be made legibly (preferably by typing) in the margins. Use universally accepted proofreader’s signs and symbols. If the authors feel the need to include new information, it should be inserted as a “Note added in proof” and will be included with the permission of the Editorial Office.

3.5 Copyright Assignment Form

Papers accepted for publication become the copyright of Acta Pharmaceutica Sinica B and authors will be asked to sign a transfer of copyright form. All authors must read and agree to the conditions outlined in the Copyright Assignment Form and must sign it. Articles will not be published until a signed Copyright Assignment Form has been received.

Authors should return the proof and Copyright Assignment Form within 3 days to the Editorial Office. If the time limit is exceeded, publication of the article may be delayed.

4. Organization of the manuscript

4.1 Title

The title of the manuscript must be informative, specific and brief (<30 words). Words should be chosen carefully to facilitate the retrieval process. Minimal use of nonfunctional words is encouraged.

4.2 Authors and affiliation

Each author should have participated sufficiently in the work to take public responsibility for the content.

Capitalize the first letter in the surname(s) and spell out the given name(s) in full-name form, e.g. Jiandong Jiang. Any change in authorship must be approved in writing by all authors. The corresponding author should be indicated by an asterisk (*) to the right of the corresponding author’s name and their telephone number, fax number and e-mail address given in the footnote. The affiliation of each author should also be given.

4.3 Abstract

The abstract should describe the aim, general methods, results and conclusions of the manuscript. It should be presented as a single paragraph following the title page.

4.4 Key words

Authors should provide 5–8 key words or phrases drawn from those recommended by the US National Library of Medicine’s Medical Subject Headings (MeSH) browser list at http://www.nlm.nih.gov/mesh/meshhome.html.

If a suitable MeSH term is not available, a more general term suitable for indexing may be used.

4.5 Text

4.5.1 Introduction: This should provide a concise summary of the topic based on relevant references and should give a clear description of the purpose of the study being reported or reviewed.

4.5.2 Materials and methods: This should provide sources of the main drugs, chemicals and instruments (including manufacturers and specifications) used in the study and should provide sufficient technical information to allow the experiments to be repeated. New methods or modifications to existing methods should be described in detail.

Drug nomenclature: International Nonproprietary Names (INN) or generic names should be employed whenever possible. The first letter of the drug name should be lowercase for INN or generic names, but capitalized for proprietary names.

Species nomenclature: The scientific names [genus, species (in italic form) and authority] of all plants, animals and microorganisms should be given. Common names may be used in certain circumstances. For crude drug names, put name of medicinal parts first (in standard form).

Experimental subjects: The authors should indicate the grade of animals used in experiments. Rats and mice should be at least specific pathogen free. The sex, age and body weight of tested animals (or humans in clinical studies) should be given as mean, standard deviation and total range. Animal experiments should adhere to instructions for the care and use of animals provided by the appropriate Ethics Committee. Human experiments may be performed only in accordance with the ethical standards and permission of the responsible committee of the institution at which the work was carried out.

4.5.3 Quantities, units, and numerical values: SI units must be used for example: length (m, cm, mm, μm, nm), mass (kg, g, mg, μg), volume (L, mL, μL), time (s, min, h, d), temperature (°C, K), radiation (Bq, dpm), concentration [mol/L, mmol/L, mg/mL, μg/mL, % (v/v), % (w/v)]. Physical quantities should be printed in italic type e.g. t (h). When an Arabic number precedes an SI unit, the unit symbol should be used rather than the full name of the unit, for example, 1 min (one minute), 2 h (two hours). No unit is required for relative molecular mass.

4.5.4 Abbreviations: These must only be used after being spelled out in full at their first appearance followed by the abbreviation in parentheses. Routes of administration may be abbreviated e.g. intravenous (iv), intramuscular (im), intraperitoneal (ip), subcutaneous (sc), intracerebroventricular (icv), intraarterial (ia), per oral (po), intragastric gavage (ig).

4.5.5 Numbers and effective digits: The effective digits in a datum are determined by the variation within the sample which is one-third of the standard deviation. For example: 4820.5 ± 340.8 g should be 4.8 ± 0.3 kg. For other expression of numbers, use 2%–6% (not 2–6%), 5×104–7×104 (not 5–7×104) and 2 mm × 3 mm × 4 mm(not 2×3×4 mm).

For further details you are referred to "Uniform Requirements for Manuscripts submitted to Biomedical Journals" (J Am Med Assoc 1997;277:927–934)

Editoral Office of Acta Pharmaceutica Sinica

1 Xiannongtan Street, Beijing 100050

Tel: 86-10-63035116, 86-10-63026192;

Fax: 86-10-63026192;

E-mail: yxxb@imm.ac.cn

http://www.yxxb.com.cn, http://www.elsevier.com/locate/apsb


本文评论

暂无相应记录!

首页<<1>>尾页共0页共0条记录
  • 万维QQ投稿交流群    招募志愿者

    版权所有 Copyright@2009-2015豫ICP证合字09037080号

     纯自助论文投稿平台    E-mail:eshukan@163.com